附件4.1
本证书所代表的证券的发行和销售以及可行使这些证券的证券 均未根据1933年修订的《证券法》或适用的州证券法进行登记。在以下情况下,证券不得出售、出售、转让或转让:(I)如果没有(A)根据修订后的1933年证券法 证券的有效注册声明,或(B)持有者的律师意见(如果公司要求),以公司合理接受的形式,根据上述法案不要求注册,或(Ii)除非根据规则144或规则144A已出售或有资格根据上述法案出售或有资格出售。尽管有上述规定,该证券仍可与博纳基金保证金账户或由该证券担保的其他贷款或融资安排有关而质押。在行使本认股权证后可发行的A系列可转换优先股的数量可能少于根据第1(A)节在本认股权证票面上列出的金额。 这份搜查令。
Lytus Technologies Holdings PTV. Ltd.
购买认股权证
A系列可转换优先股
优先认股权证编号:PW-[]
签发日期:_, [] 20__ (“发行日期 日期“)
Lytus Technologies Holdings PTV。有限公司,一家根据英属维尔京群岛法律成立的公司(“公司”),特此证明,以良好和有价值的代价,在此确认收到和充分,[买家], 本协议的登记持有人或其获准受让人(“持有人”)有权在发行日期当日或之后的任何时间,但在纽约时间下午11:59之后,有权按当时有效的行使价(定义如下)从本公司购买A系列可转换优先股(包括购买A系列可转换优先股的任何认股权证,以交换、转让或替换A系列可转换优先股,即“认股权证”)。在到期日(定义如下),[________]A系列可转换优先股(“认股权证优先股”)的缴足股款及不可评估的股份(“认股权证优先股”)。除本文另有定义外,本认股权证中的大写术语应具有第18节中给出的含义。本认股权证是根据该特定证券购买协议第1节发行的A系列可转换优先股(“SPA优先股权证”)之一(见证券购买协议(定义见下文)),日期为2023年8月31日(“认购日期”),由本公司及其中所指的投资者(“买方”)发行。经不时修订(“证券购买协议”)。
1. 手令的行使。
(A)锻炼的力学。在本协议条款及条件的规限下,本认股权证持有人可于 发行日期(“行使日期”)当日或之后的任何一天,以 持有人选择行使本认股权证的方式,以附件A(“行使通知”)的形式递交一份 书面通知(不论是否透过电邮或其他方式),全部或部分行使本认股权证。在上述行使本认股权证后的一(1)个交易日(定义见下文)内,持有人须以现金或即时可动用资金电汇的方式,向本公司支付一笔款项,数额相等于行使该认股权证当日有效的行使价乘以行使本认股权证的优先股数目(“行权价合计”)。持有人无需交付本授权书正本即可行使本授权证。就少于全部认股权证优先股签立及交付行权通知,与取消本认股权证原件及发行证明有权购买剩余数量认股权证优先股的新认股权证具有同等效力。 就当时剩余的所有认股权证优先股签立及交付行权通知,与根据本条款交付认股权证优先股后注销本认股权证原件具有同等效力。在 或第二个(2)之前发送) Trading Day following the date on which the Company has received such Exercise Notice (or such earlier date as required pursuant to the 1934 Act or other applicable law, rule or regulation for the settlement of a trade of such Warrant Preferred Shares initiated on the applicable Exercise Date), the Company shall issue and deliver (via reputable overnight courier) to the address as specified in the Exercise Notice, a certificate, registered in the name of the Holder or its designee, for the number of Warrant Preferred Shares to which the Holder shall be entitled pursuant to such exercise. Upon delivery of an Exercise Notice and the release, at the direction of the Holder, of a wire (or irrevocable wire instructions to send the wire as soon as commercially practicable, but in no event later than the next Trading Day) of the Aggregate Exercise Price to the Company (the “Exercise Conditions”), the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Preferred Shares with respect to which this Warrant has been exercised (including, without limitation, the right to convert such Warrant Preferred Shares), irrespective of the date of delivery of the certificates evidencing such Warrant Preferred Shares (as the case may be). If a certificate with respect to this Warrant is delivered to the Company in connection with any exercise pursuant to this Section 1(a) and the number of Warrant Preferred Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Preferred Shares being acquired upon an exercise, then, at the request of the Holder, the Company shall as soon as practicable and in no event later than two (2) Business Days after any exercise and at its own expense, issue and deliver to the Holder (or its designee) a new Warrant (in accordance with Section 6(d)) representing the right to purchase the number of Warrant Preferred Shares purchasable immediately prior to such exercise under this Warrant, less the number of Warrant Preferred Shares with respect to which this Warrant is exercised. No fractional Warrant Preferred Shares are to be issued upon the exercise of this Warrant, but rather the number of Warrant Preferred Shares to be issued shall be rounded up to the nearest whole number. The Company shall pay any and all transfer, stamp, issuance and similar taxes, costs and expenses that may be payable with respect to the issuance and delivery of Warrant Preferred Shares upon exercise of this Warrant. Notwithstanding the foregoing, the Company’s failure to deliver Warrant Preferred Shares to the Holder on or prior to the later of (i) two (2) Trading Days after receipt of the applicable Exercise Notice (or such earlier date as required pursuant to the 1934 Act or other applicable law, rule or regulation for the settlement of a trade of such Warrant Preferred Shares initiated on the applicable Exercise Date) and (ii) one (1) Trading Day after the Company’s receipt of the Aggregate Exercise Price (such later date, the “Share Delivery Deadline”) shall not be deemed to be a breach of this Warrant. For the avoidance of doubt, the Holder may convert the Warrant Preferred Shares into Common Shares in accordance with the terms of the Certificate of Designations at any time, at the option of the Holder, following its satisfaction of the applicable Exercise Conditions (whether or not a certificate with respect to such Warrant Preferred Shares has been delivered to the Holder on or prior to such time of conversion).
2
(b) 行使价。就本认股权证而言,“行使价”是指850.00美元,可根据 的规定进行调整。
(c) 争议。如果就行使价的确定或根据本协议条款将发行的认股权证优先股数量 的算术计算产生争议,公司应立即向持有人发行无争议的认股权证优先股数量 ,并根据第14条解决该争议。
(d) 强迫运动。
(I)一般。 在本协议日期一周年之前的任何时间,只要(I)当时不存在股权条件失效(除非持有人书面放弃),以及(Ii)在紧接适用的决定日期(每个该等适用日期,“强制行使资格日期”)之前的五(5)个交易日内未发生强制行使(定义见下文),公司即有权要求持有人行使本认股权证,有效发行的 和不可评估的认股权证优先股,相当于(X)持有者按比例持有500股认股权证优先股和 (Y)该等认股权证优先股的最大数目,该等认股权证优先股于截至该强制行使通知日期前一个交易日的替代换股价(定义见 指定证书)全数转换时(不考虑指定证书就此设定的任何 行使限制)不超过普通股总交易量的30%(不受指定证书所载的任何 行使限制)(证券购买协议)(彭博社报道)在连续五(5)个交易日结束的 交易日期间,并包括适用强制行使通知日期(定义见下文)的前一个交易日(该等较少数量的认股权证优先股,“最高强制行使股份金额”),如将根据本协议第1(A)节发出及交付的 适用强制行使通知(定义见下文)(每一份为 “强制行使”)所指定。本公司可根据第1(D)条行使其要求强制行使的权利,方法是在强制行使资格之日,通过电子邮件一次或多次向SPA优先认股权证的所有(但不少于所有)持有者发送有关的书面通知 (每个“强制行使通知”及其日期) 。就本协议第1(A)节而言,“强制行使通知”应被视为 以取代“行使通知”,如同持有人在强制行使通知日期 向公司递交了行使通知一样。作必要的变通。每一强制行使通知都是不可撤销的。每份强制行使通知应说明:(I)根据本第1(D)条为强制行使选择的交易日,该交易日应为适用的强制行使通知日(每个强制行使日)之后的第二(2)个交易日(或持有人以书面形式向公司指定的较早日期),(Ii)本认股权证及SPA优先认股权证的合计部分 根据第1(D)条 (以及SPA优先认股权证的类似条文),(Iii)适用于持有人的最高强制行使股份金额(包括计算及持有人就此合理要求的任何其他文件),及(Iv)并无任何股权条件失效(或指明当时存在的任何该等股权条件失效,并确认除非放弃该等股权条件),该强制行使通知全部或部分无效)。尽管本协议有任何相反规定 ,如果强制行使通知日期之后且在该等适用强制行使完成之前的任何时间发生股权条件失效,(A)本公司应向持有人发出表明此意的后续通知,以及(B)除非持有人 放弃适用的股权条件失效,否则强制行使应被取消,且适用的强制行使通知应 无效。为免生疑问,如果任何触发事件已经发生并继续发生,除非该触发事件(如指定证书中所定义的)已由持有人以书面形式全部或部分放弃,否则公司无权强制行使;但该触发事件(视情况而定)不应影响持有人行使本认股权证的权利。尽管如上所述,本公司有权(X)选择要求强制行使和/或(Y)完成任何未决的强制行使,在该权利中,本公司已适当地向 持有人发送强制行使通知(视情况而定),应在本公司和/或其任何附属公司(视情况而定)直接或间接(A) 签订一项或多项协议以发出、要约、出售、授予购买或以其他方式处置任何股权证券或任何股权挂钩证券或相关证券(包括但不限于根据1933年法令颁布的规则405定义的任何“股权证券”)、任何可转换证券和/或任何适用的期权(在每种情况下,除《证券购买协议》所界定的除外证券外)的任何选择权或权利,总收益至少为200万美元(为此目的,假设根据或按照该协议发行的所有此类证券,如 适用,(B)于认购日起至到期日止期间内任何时间,与持有人以外的任何人士(各“触发 后续配售”)及/或(B)完成任何触发后续配售。
3
(ii) 按比例执行要求。如果本公司选择根据本 1(d)条强制行使本认股权证,则本公司必须就所有SPA优先认股权证同时以相同比例采取相同行动。
(e) Reservation of Shares. So long as this Warrant remains outstanding, the Company shall at all times keep reserved for issuance under this Warrant a number of Series A Convertible Preferred Shares at least equal to 100% of the maximum number of Series A Convertible Preferred Shares as shall be necessary to satisfy the Company’s obligation to issue Series A Convertible Preferred Shares under the SPA Preferred Warrants then outstanding (without regard to any limitations on exercise) (the “Required Reserve Amount”); provided that at no time shall the number of Series A Convertible Preferred Shares reserved pursuant to this Section 1(d) be reduced other than proportionally in connection with any exercise or redemption of SPA Preferred Warrants or such other event covered by Section 2(a) below. The Required Reserve Amount (including, without limitation, each increase in the number of shares so reserved) shall be allocated pro rata among the holders of the SPA Preferred Warrants based on number of Series A Convertible Preferred Shares issuable upon exercise of SPA Preferred Warrants held by each holder on the Closing Date (without regard to any limitations on exercise) or increase in the number of reserved shares, as the case may be (the “Authorized Share Allocation”). In the event that a holder shall sell or otherwise transfer any of such holder’s SPA Preferred Warrants, each transferee shall be allocated a pro rata portion of such holder’s Authorized Share Allocation. Any Series A Convertible Preferred Shares reserved and allocated to any Person which ceases to hold any SPA Preferred Warrants shall be allocated to the remaining holders of SPA Preferred Warrants, pro rata based on the number of Warrant Preferred Shares issuable upon exercise of the SPA Preferred Warrants then held by such holders (without regard to any limitations on exercise). If, notwithstanding the foregoing, and not in limitation thereof, at any time while any of the SPA Preferred Warrants remain outstanding, the Company does not have a sufficient number of authorized and unreserved Series A Convertible Preferred Shares to satisfy its obligation to reserve the Required Reserve Amount (an “Authorized Share Failure”), then the Company shall immediately take all action necessary to increase the Company’s authorized Series A Convertible Preferred Shares to an amount sufficient to allow the Company to reserve the Required Reserve Amount for all the SPA Preferred Warrants then outstanding. Without limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share Failure, but in no event later than sixty (60) days after the occurrence of such Authorized Share Failure, the Company shall hold a meeting of its shareholders for the approval of an increase in the number of authorized Series A Convertible Preferred Shares. In connection with such meeting, the Company shall provide each shareholder with a proxy statement and shall use its best efforts to solicit its shareholders’ approval of such increase in authorized Series A Convertible Preferred Shares and to cause its board of directors to recommend to the shareholders that they approve such proposal. Notwithstanding the foregoing, if any such time of an Authorized Share Failure, the Company is able to obtain the written consent of a majority of its issued and outstanding Series A Convertible Preferred Shares to approve the increase in the number of authorized Series A Convertible Preferred Shares, the Company may satisfy this obligation by obtaining such consent and submitting for filing with the SEC an Information Statement on Schedule 14C.
4
2.调整练习价格和不动产股票数量。行使价和在行使本认股权证时可发行的认股权证优先股数量 可根据本第2节的规定不时进行调整。
(a) Share dividends and Splits. If the Company, at any time on or after the Subscription Date, (i) pays a share dividend on one or more classes of its then outstanding Warrant Preferred Shares or otherwise makes a distribution on any class of share capital that is payable in Warrant Preferred Shares, (ii) subdivides (by any share split, share dividend, recapitalization or otherwise) one or more classes of its then outstanding Warrant Preferred Shares into a larger number of shares or (iii) combines (by combination, reverse share split or otherwise) one or more classes of its then outstanding Warrant Preferred Shares into a smaller number of shares then in each such case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Warrant Preferred Shares outstanding immediately before such event and of which the denominator shall be the number of Warrant Preferred Shares outstanding immediately after such event. Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution, and any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination. If any event requiring an adjustment under this paragraph occurs during the period that an Exercise Price is calculated hereunder, then the calculation of such Exercise Price shall be adjusted appropriately to reflect such event.
(b) 认股权证优先股数量。在根据本第2条对行使价进行任何调整的同时, 在行使本认股权证时可购买的认股权证优先股数量应按比例增加或减少, 因此,在该等调整后,根据调整后数量的认股权证优先股应付的总行使价应 与紧接该等调整前有效的总行使价相同(不考虑本文所载的任何行使限制 )。
(c) 公司自愿调整。根据主要市场的规则和法规,本公司可在本认股权证有效期内的任何时间 ,经要求持有人(定义见证券购买协议)的事先书面同意, 在本公司董事会认为适当的任何时间内,将当时的行使价降低至任何数额。
5
3. 基本交易。
(a) Fundamental Transactions. The Company shall not enter into or be party to a Fundamental Transaction unless (i) the Successor Entity assumes in writing all of the obligations of the Company under this Warrant and the other Transaction Documents (as defined in the Securities Purchase Agreement) in accordance with the provisions of this Section 3(a) pursuant to written agreements in form and substance satisfactory to the Holder and approved by the Holder prior to such Fundamental Transaction, including agreements to deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant, including, without limitation, which is exercisable for a corresponding number of share capital equivalent to the shares of Series A Convertible Preferred Shares acquirable and receivable upon exercise of this Warrant prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such share capital (but taking into account the relative value of the shares of Series A Convertible Preferred Shares pursuant to such Fundamental Transaction and the value of such share capital, such adjustments to the number of share capital and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction) and (ii) the Successor Entity (including its Parent Entity) is a publicly traded corporation whose common equity is quoted on or listed for trading on an Eligible Market. Upon the consummation of each Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of the applicable Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein. Upon consummation of each Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon exercise of this Warrant at any time after the consummation of the applicable Fundamental Transaction, in lieu of the shares of Series A Convertible Preferred Shares (or other securities, cash, assets or other property) issuable upon the exercise of this Warrant prior to the applicable Fundamental Transaction, such shares of publicly traded common stock (or its equivalent) of the Successor Entity (including its Parent Entity) which the Holder would have been entitled to receive upon the happening of the applicable Fundamental Transaction had this Warrant been completely exercised (and the underlying Warrant Preferred Shares completely converted) immediately prior to the applicable Fundamental Transaction (without regard to any limitations on the conversion of the Warrant Preferred Shares), as adjusted in accordance with the provisions of this Warrant. Notwithstanding the foregoing, the Holder may elect, at its sole option, by delivery of written notice to the Company to waive this Section 3(a) to permit the Fundamental Transaction without the assumption of this Warrant. In addition to and not in substitution for any other rights hereunder, prior to the consummation of each Fundamental Transaction pursuant to which holders of Common Shares are entitled to receive securities or other assets with respect to or in exchange for Common Shares (a “Corporate Event”), the Company shall make appropriate provision to insure that the Holder will thereafter have the right to receive upon an exercise of this Warrant and conversion of the underlying Warrant Preferred Shares at any time after the consummation of the applicable Fundamental Transaction but prior to the Expiration Date, in lieu of the Common Shares (or other securities, cash, assets or other property) issuable upon the exercise of the Warrant and conversion of the underlying Warrant Preferred Shares prior to such Fundamental Transaction, such shares, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription rights) which the Holder would have been entitled to receive upon the happening of the applicable Fundamental Transaction had this Warrant been exercised and converted into Warrant Preferred Shares immediately prior to the applicable Fundamental Transaction (without regard to any limitations on the exercise of this Warrant). Provision made pursuant to the preceding sentence shall be in a form and substance reasonably satisfactory to the Holder.
6
(b) 申请。本第3节的规定应类似且平等地适用于后续基本交易 和公司事件,并应如同本认股权证(及任何该等后续认股权证)可完全行使而适用,而不考虑 对本认股权证行使的任何限制。
4.《不循环公约》。本公司特此 承诺并同意,本公司不会通过修改其公司章程,(定义见证券购买协议), 章程(定义见证券购买协议)或通过任何重组、资产转让、合并、合并、安排方案、解散、发行或出售证券,或任何其他自愿行动,避免或寻求避免遵守或履行本认股权证的任何条款,并将始终本着诚意执行本认股权证的所有条款,并采取可能需要的一切行动 保护持有人的权利。在不限制上述规定的一般性的情况下,公司(a)不得增加 任何应收认股权证优先股的面值高于当时生效的行使价,及 (b)应采取一切必要或适当的行动,以使公司可有效合法地发行已缴足 及非此优先股的行使权,是行使此优先股的。
5. WARRANT HOLDER NOT DEEMED A SHAREHOLDER. Except as otherwise specifically provided herein, the Holder, solely in its capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in its capacity as the Holder of this Warrant, any of the rights of a shareholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of shares, reclassification of shares, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Preferred Shares which it is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a shareholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company, except to the extent required, from time to time, pursuant to Section 1(d) herein. Notwithstanding this Section 5, the Company shall provide the Holder with copies of the same notices and other information given to the shareholders of the Company generally, contemporaneously with the giving thereof to the shareholders. Notwithstanding anything herein to the contrary, if after the sixty (60) calendar day anniversary of the Issuance Date, the Holder is not permitted to exercise this Warrant in full for any reason, the Company shall use its best efforts to promptly remedy such failure, including, without limitation, obtaining such consents or approvals as necessary to permit such exercise into Series A Convertible Preferred Shares.
7
6. 重新发行认股权证。
(a) 转让权证。如果转让本认股权证,持有人应将本认股权证交回本公司,然后 本公司将根据持有人的命令立即签发并交付一份新认股权证(根据第6(d)条),应持有人要求登记 ,代表购买持有人转让的认股权证优先股数量的权利,以及, 如果转让的认股权证优先股总数少于该认股权证的认股权证优先股总数,则向持有人提交一份新认股权证(根据 第6(d)条),代表购买未转让认股权证优先股数量的权利。
(b) 遗失、被盗或损毁的令状。公司收到令公司合理满意的证据,证明 本认股权证丢失、被盗、销毁或损坏(书面证明和下文考虑的赔偿 应足以作为证据),以及在损失、被盗或毁坏的情况下,持有人以惯常和合理的形式向 公司作出的任何赔偿承诺,以及,如果发生破坏,则在交出和取消本认股权证后,公司 应签署并向持有人交付一份新认股权证(根据第6(d)条),该认股权证代表购买当时本认股权证所依据的认股权证优先股的权利。
(c) 可交换多个权证。持有人在本公司主要办事处交回本认股权证后,本认股权证可更换为新认股权证(根据第6(d)条)合计代表购买当时本认股权证基础上的认股权证优先股数量的权利,而每份该等新认股权证将代表购买 持有人在该等交回时指定的该等认股权证优先股部分的权利;然而,前提是不发出零碎认股权证优先股的认股权证 。
(D)发行新的 权证。当本公司须根据本认股权证条款发行新认股权证时,该新认股权证(I) 应与本认股权证具有相同期限,(Ii)如该新认股权证表面所示,代表购买当时作为本认股权证基础的认股权证优先股的权利(或如根据第6(A)条或第6(C)条发行新认股权证,则为持有人指定的认股权证优先股,当与该等发行相关而发行的其他新认股权证的优先股数目相加时,不超过本认股权证当时的认股权证数量(br}优先股),(Iii)发行日期应与新认股权证的发行日期相同 ,及(Iv)拥有与本认股权证相同的权利及条件。
8
7.通知。除非本认股权证另有规定,否则当根据本认股权证需发出通知时,应根据证券购买协议第9(F)节作出通知。本公司应向持有人提供根据本认股权证采取的所有行动(根据本条款行使时发行认股权证优先股除外)的即时书面通知,包括合理详细的行动描述 及其原因。在不限制前述一般性的情况下,本公司将向 持有人发出书面通知:(I)每次调整行使价和认股权证优先股数量时,应立即合理地详细列出并证明该等调整的计算方法(S);(Ii)在本公司结清账簿或就任何基本交易、解散或清算确定投票权的日期前至少十五(15)天; 在每种情况下,应在向持有人提供通知之前或与通知一起向公众公布相关信息 ,(Iii)在任何基本交易完成前至少十(10)个交易日,以及(Iv)在触发事件发生的一(1)个业务 日内(定义见指定证书),合理详细地列出与该触发事件有关的任何重大事件以及本公司为治愈该触发事件所做的任何努力。若本公告 构成或包含有关本公司或其任何附属公司(定义见证券购买协议)的重要非公开信息,本公司应同时根据境外发行人的6-K表格报告向美国证券交易委员会(定义见证券购买协议)提交该等通知。如果本公司或其任何附属公司向持有人提供重要的非公开信息,而该信息并未同时在《境外发行者当前报告》中以Form 6-K的形式提交,并且持有人未同意 接收该等重大非公开信息,则公司特此约定并同意,持有人对公司、其任何子公司或其各自的任何高级管理人员、董事、员工、关联公司或代理不负有任何保密责任, 或对上述任何人负有不基于该等重大非公开信息进行交易的责任。已明确理解并同意 持有人在每份行使通知中指定的执行时间应为最终时间,公司不得对此提出异议或质疑。
8.管理公开公司 交付给持有人后(或本公司从持有人处收到)根据本认股权证条款的任何通知,除非本公司 已真诚地确定与该通知有关的事项不构成与本公司或其任何子公司有关的重大、非公开信息,本公司应于9日或之前:在紧接该通知送达日期后的营业日,纽约市时间上午00点,公开披露有关外国发行人报告的材料、非公开信息(表格6—K或其他)。 如果公司认为通知包含与公司或其任何子公司有关的重大非公开信息, 公司应在该通知中以书面方式明确向持有人表明(或在收到持有人的通知后立即, 视情况而定),而在该通知中没有任何该等书面指示的情况下,(或本公司在收到持有人通知后立即发出通知 ),持有人应有权推定该通知所载信息不构成重要, 与本公司或其任何子公司有关的非公开信息。本第8条中的任何内容均不限制本公司在证券购买协议第4(i)条下的任何义务或持有人的任何权利。
9
9. 没有交易和披露限制。本公司承认并同意持有人不是本公司的受托人或 代理人,持有人没有义务(a)对 本公司提供的任何信息保密,或(b)在没有书面保密的情况下,在持有该等信息的情况下,不得买卖任何证券 由持有人的高级官员签署的协议,明确规定了此类保密和交易限制。在没有 此类已签署的书面保密协议的情况下,本公司承认持有人可以自由买卖本公司发行的任何证券 ,可以拥有和使用本公司提供的与此类交易活动有关的任何信息,并可以向任何第三方披露 任何此类信息。
10.修正案 和豁免。除本协议另有规定外,本认股权证的条款可予修订,且本公司可采取 本协议禁止的任何行动,或不执行本协议要求其执行的任何行动,但只有在本公司已获得持有人的 书面同意的情况下。除非以书面形式并由 放弃方的授权代表签署,否则放弃方无效。
11.可分割性 如果本认股权证的任何条款被法律禁止,或被有管辖权的 法院以其他方式确定为无效或不可执行,则本应被禁止、无效或不可执行的条款应被视为经修改,以适用于 其有效和可执行的最广泛范围,只要经修改的本权证继续表明,该条款的无效性或不可撤销性不应影响本权证其余条款的有效性,在没有 实质性变更的情况下,当事人对本协议标的的原始意图以及相关条款的禁止性质、无效性或 不可撤销性不会实质性地损害当事人各自的期望或互惠义务 ,或实际实现本应赋予当事人的利益。双方将 努力通过真诚协商,以有效条款取代禁止、无效或不可执行的条款,该条款 的效力应尽可能接近禁止、无效或不可执行的条款。
10
12.管辖 法律。本授权书应受纽约州国内法律管辖、解释和执行,所有有关本授权书的解释、有效性、解释和执行的问题均应受纽约州国内法律管辖,但不适用任何可能导致纽约州以外任何司法管辖区的法律适用的法律选择或冲突法律条款或规则(无论是纽约州还是任何其他司法管辖区)。本公司在此不可撤销地放弃面交送达法律程序文件,并同意在任何此类诉讼、诉讼或法律程序中被送达的法律程序文件, 将其副本按证券购买协议第9(F)条规定的地址邮寄给本公司,并同意 该等送达应构成良好和充分的法律程序文件及其通知的送达。公司在此不可撤销地将位于纽约州曼哈顿区纽约市的州法院和联邦法院的专属管辖权提交给 ,以裁决本协议项下或与本协议相关的任何争议, 并在此不可撤销地放弃并同意不在任何诉讼、诉讼或法律程序中主张其本人不受任何此类法院的管辖权、该等诉讼、诉讼或法律程序是在不方便的法庭提起,或该诉讼、诉讼或法律程序的地点不适当的任何主张。此处包含的任何内容均不得视为以任何方式限制以法律允许的任何方式送达程序的任何权利。本协议所载内容不应被视为或阻止持有人在任何其他司法管辖区对本公司提起诉讼或采取其他法律行动,以追讨本公司对持有人的义务,将该等义务的任何抵押品或任何其他担保变现,或强制执行对持有人有利的判决或其他法院裁决。如果根据上述判决完成了法律程序文件的送达,则根据纽约州的法律,该等文件的送达将被视为充分的,公司不得以其他方式断言。此处包含的任何内容均不得视为以任何方式限制 以法律允许的任何方式送达过程的任何权利。本协议所载任何事项均不得视为或妨碍持有人在任何其他司法管辖区对本公司提起诉讼或采取其他法律行动,以追讨本公司对该买家的责任,或执行对持有人有利的判决或其他法庭裁决。本公司(代表本公司及其各附属公司)特此委任证券购买协议附表9(A)所列送达法律程序文件的代理人为其在纽约的送达法律程序文件代理人。公司在此不可撤销地放弃其可能拥有的任何权利,并同意不要求陪审团审判,以裁决因本认股权证或本协议拟进行的任何交易而产生的任何争议,或与或 相关的纠纷。选择纽约州法律作为本认股权证的管辖法律是一种有效的法律选择,并将在英属维尔京群岛和印度或适用于公司或其任何子公司的具有管辖权的法院提起的任何诉讼中得到承认并生效,但下列法律除外:(I)该法院认为具有程序性质的法律;(Ii)税收或刑法法律;或(Iii)其适用与公共政策相抵触的法律。根据英属维尔京群岛的法律和适用于本公司或其任何附属公司的印度或该等其他司法管辖区的法律解释该术语。公司或其各自的任何财产、资产或收入,根据英属维尔京群岛和印度的法律或适用于公司或其任何子公司或纽约州法律的其他司法管辖区的法律,不享有任何法律诉讼、诉讼或法律程序的豁免权,在任何此类法律诉讼、诉讼或法律程序中给予任何救济,从任何英属维尔京群岛和印度的司法管辖区或适用于公司或其任何子公司或任何纽约或美国联邦法院的司法管辖区获得法律程序文件的送达豁免。在判决之时或之前扣押,或因执行判决而扣押,或因执行判决而扣押,或因其他法律程序或法律程序而扣押,以便在任何该等法院就其义务、法律责任或交易文件项下、所引起或与交易文件有关之任何其他事宜给予任何济助或强制执行判决;此外,在本公司或其任何财产、资产或收入可能有权或此后可能有权在任何该等法院享有任何该等豁免权的范围内,本公司特此在法律许可的范围内放弃该等权利,并据此 同意本认股权证及其他交易文件所规定的救济及强制执行。
11
13.施工; 个标题。本认股权证应被视为由本公司和持有人共同起草,不得被解释为针对任何人作为本认股权证的起草人。本授权书的标题仅供参考,不得构成本授权书的一部分,也不影响本授权书的解释。本认股权证中使用但在其他交易文件中定义的术语应具有该等其他交易文件中截止日期(定义见证券购买协议)的该等术语的含义 除非持有人另有书面同意。
14.争议解决。
(A)提交 争议解决方案。
(I) 如果争议涉及行使价或公允市值或认股权证数量的算术计算(视情况而定)(包括但不限于与上述任何事项的确定有关的争议),则公司或持有人(视情况而定)应通过电子邮件将争议提交给另一方:(A)如果是公司, 在引起争议的情况发生后两(2)个工作日内,或(B)如果是由持有人,在持有人得知引起此类纠纷的情况后的任何时间。如果持有人和本公司不能迅速解决与该行使价或该公允市值或该认股权证优先股数量的算术计算(视情况而定)有关的争议,则在第二次(2)之后的任何时间发送)在本公司或该争议的持有人(视属何情况而定)向本公司或持有人(视属何情况而定)发出该等初步通知后的营业日内,则该持有人可根据其唯一选择,选择一家独立、信誉良好的投资银行来解决该争议。
(Ii)持有人和本公司应分别向该投资银行交付(A)根据本第14条第一句在 中提交的初始争议提交的副本和(B)支持其对该争议的立场的书面文件,在任何情况下,均不迟于下午5:00。(纽约时间)5日(5日)这是)紧接持有人选择此类投资银行之日(“争议提交截止日期”)之后的营业日(前一条款(A)和(B)中所指的文件在本文中统称为“所需争议文件”)(双方理解并同意,如果持有人或公司未能在争议提交截止日期前提交所有所需的争议文件,则未能提交所有所需争议文件的一方将不再有权(并在此放弃其权利)向该投资银行交付或提交与该争议有关的任何书面文件或其他支持,而该投资银行应仅根据在提交争议截止日期前提交给该投资银行的所需争议文件来解决该争议)。除非 本公司和持有人另有书面同意或该投资银行另有要求,否则本公司和持有人均无权向该投资银行交付或提交与该争议有关的任何书面文件或其他支持(所要求的争议文件除外)。
12
(Iii) 本公司和持有人应促使该投资银行确定该争议的解决方案,并在紧接争议提交截止日期后十(10)个工作日内将该解决方案通知本公司和持有人。投资银行对此类争议的解决是终局的,对没有明显错误的各方都具有约束力。
(Iv)任何合理的费用和/或费用,包括所有各方的所有合理律师费和/或投资银行的合理费用,应在争议解决时由败诉方支付。
(B)其他。本公司明确承认并同意:(I)本第14条构成公司与持有人之间的仲裁协议(并构成仲裁协议),根据《纽约民事实践法和规则》(以下简称《CPLR》)第7501条及以下规定当时有效的规则,并且持有人或公司有权根据CPLR第7503(A)条申请强制仲裁的命令,以迫使遵守本第14条,(Ii)本认股权证的条款和每一份其他适用的交易文件应作为选定投资银行解决适用争议的基础,该投资银行有权(并在此获得明确授权)作出该投资银行确定的与其解决该争议有关的所有发现、决定等,持有人有权自行决定将本第14条所述的任何争议提交给位于纽约曼哈顿区纽约市的任何州或联邦法院,除使用第14条所述的程序外,第14条和(Iii)第14条的任何规定均不限制持有人获得任何禁令救济或其他衡平法救济 (包括但不限于第14条所述的任何事项)。
13
15. REMEDIES, CHARACTERIZATION, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant and the other Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder to pursue actual and consequential damages for any failure by the Company to comply with the terms of this Warrant. The Company covenants to the Holder that there shall be no characterization concerning this instrument other than as expressly provided herein. Amounts set forth or provided for herein with respect to payments, exercises and the like (and the computation thereof) shall be the amounts to be received by the Holder and shall not, except as expressly provided herein, be subject to any other obligation of the Company (or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of this Warrant shall be entitled, in addition to all other available remedies, to specific performance and/or temporary, preliminary and permanent injunctive or other equitable relief from any court of competent jurisdiction in any such case without the necessity of proving actual damages and without posting a bond or other security. The Company shall provide all information and documentation to the Holder that is requested by the Holder to enable the Holder to confirm the Company’s compliance with the terms and conditions of this Warrant (including, without limitation, compliance with Section 2 hereof). The issuance of shares and certificates for shares as contemplated hereby upon the exercise of this Warrant shall be made without charge to the Holder or such shares for any issuance tax or other costs in respect thereof, provided that the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of any certificate in a name other than the Holder or its agent on its behalf.
16. 收取、执行和其他费用的支付。如果(a)本认股权证被 交由律师进行催收或执行,或通过任何法律程序被催收或执行,或持有人 采取行动收回根据本认股权证应付的款项或执行本认股权证的条款,或(b)发生任何破产, 重组,公司的接管或其他影响公司债权人权利并涉及 本认股权证项下的索赔的诉讼,则公司应支付持有人因该等收款而产生的费用,强制执行或诉讼,或与此类破产、重组、接管或其他程序有关,包括但不限于律师费和支出。
17.转移 本认股权证可在未经本公司同意的情况下被要约出售、出售、转让或转让,但证券购买协议第2(g)条另有要求 除外。
18.某些定义。就本认股权证而言,下列术语具有以下含义:
(A) “1933年法案”系指经修订的1933年证券法及其下的规则和条例。
(B)“1934年法案”系指经修订的1934年证券交易法及其下的规则和条例。
14
(c) "关联公司"是指,就任何人而言,直接或间接控制该人、受该人 控制或与该人共同控制的任何其他人,就本定义而言, 个人的"控制"是指直接或间接地以10%或以上的普通投票权股份投票选举 或通过合同或其他方式指导或促使指导该人的管理层和政策。
(D) “彭博”指彭博,L.P.
(e) "营业日"指除星期六、星期日或法律规定纽约市商业银行 被授权或要求继续关闭的其他日子以外的任何日子;然而,如果为了澄清,商业银行不应被视为被授权或法律要求保持关闭,因为"呆在家里", "避难","非必要雇员"或任何其他类似命令或限制,或在任何政府当局的指示下关闭任何实体分行,只要纽约市商业银行的电子资金转账系统(包括电汇)在该日一般开放供客户使用。
(f)“指定证书”是指本公司A系列可转换优先股 的指定证书,日期为2023年8月31日,并不时修订。
(g) "普通股"是指(i)公司的普通股,每股面值0.01美元,以及(ii)将该等普通股变更为的任何股本 或因该等普通股重新分类而产生的任何股本。
(h) “普通认股权证”具有证券购买协议中赋予该术语的含义,并应包括 为交换或替换而发行的所有认股权证。
(i) "合格市场"指纽约证券交易所、纽约美国证券交易所、纳斯达克全球精选市场、 纳斯达克全球市场或主要市场。
(j)“股权条件”指,就任何给定的确定日期而言:
(i) on such applicable date of determination (x) one or more Registration Statements (each, the “Forced Exercise Registration Statement”) filed pursuant to the Registration Rights Agreement (as defined in the Securities Purchase Agreement) shall be effective and the prospectus contained therein shall be available on such applicable date of determination (with, for the avoidance of doubt, any shares of Common Shares previously sold pursuant to such prospectus deemed unavailable) for the resale of all shares of Common Shares (the “Conversion Shares”) issuable upon conversion of the Series A Convertible Preferred Shares then outstanding and such Warrant Preferred Shares to be issued in connection with the event requiring such determination, without regard to any limitations on conversion set forth in the Certificate of Designations, at the Floor Price (as defined in the Certificate of Designations) then in effect (such applicable aggregate number of shares of Common Shares, each, a “Required Minimum Securities Amount”) in accordance with the terms of the Registration Rights Agreement and there shall not have been during such period any Grace Periods (as defined in the Registration Rights Agreement), or (y) all Registrable Securities (as defined in the Registration Rights Agreement) shall be eligible for sale pursuant to Rule 144 (as defined in the Securities Purchase Agreement) without the need for registration under any applicable federal or state securities laws (in each case, disregarding any limitation on conversion of the Series A Convertible Preferred Shares and exercise of the Common Warrants);
15
(ii) 自适用裁定日期前三十(30)个日历日开始至 (包括适用裁定日期)止期间的每一天(“权益状况计量期”),普通股(包括 在转换当时尚未发行的A系列可换股优先股时发行的所有普通股股份和认股权证优先股 在需要作出此决定的情况下将予发行的股份)已上市或指定报价(如适用)在合资格市场 ,且不得暂停在合资格市场交易(不包括暂停不超过两(2)个交易日和 在适用的确定日期之前因公司的业务公告而发生)合格市场的退市或暂停 也不会受到威胁(在所有适用通知生效后,有合理的可能被除名, 上诉,合规期和听证期)或合理可能发生或待决,如(A)该合资格市场的书面证明 或(B)公司低于合格市场的最低上市维持要求,普通股随后 上市或指定报价(如适用);
(iii) 在股权条件计量期内,公司应按照本协议第1条的规定及时交付因行使本认股权证而发行的所有认股权证优先股,以及按照其他交易文件的规定, 公司要求及时交付的所有其他股本;
(Iv) 与需要确定的事件有关而发行的任何认股权证优先股以及所需的最低证券金额 与此相关并可在转换当时尚未发行的A系列可转换优先股时发行的 (在每种情况下,不考虑指定证书中规定的转换限制和当时有效的替代转换 价格)可在不违反普通股当时上市或指定报价的合资格市场的规则或规定的情况下全部发行;
16
(V) 在股权条件测量期内的每一天,不得发生未被放弃、终止或完成的未决、拟议或拟进行的基本面交易的公告。
(Vi)本公司不应知悉任何合理预期会导致适用的强制行使登记 声明失效或其中所载招股说明书不能供持有人转售的任何事实,该声明涉及当时已发行的所有优先股及任何认股权证优先股的最低证券金额,并与有关决定有关,且不存在或持续不存在当前的公共信息失灵(定义见 登记权协议);
(Vii)持有人不得拥有本公司、其任何子公司或其各自的关联公司、员工、高级管理人员、代表、代理等向他们中的任何人提供的任何重大、非公开信息;
(Viii)在股权条件测量期内的每一天,本公司在其他方面应遵守每项规定,且不应 违反任何重大方面的任何陈述或保证(受重大不利影响或重要性的陈述或保证除外,不得在任何方面违反)或任何交易文件的任何契诺或其他条款或条件,包括但不限于,本公司不应未能根据任何交易文件及时支付任何款项;
(Ix)在适用的确定日期,不应发生任何数量故障或价格故障;
(x) 于适用的厘定日期(A)无授权股份失效(如上文第1节(e)项所定义)应存在或持续存在, (B)与需要作出此决定的事件有关而发行的所有认股权证优先股可全额发行,而不会 导致授权股份失效(如上文第1(e)节所定义)及(C)在转换该等认股权证优先股及当时尚未发行的A系列可转换优先股时,(假设为此目的, 当时发行在外的所有A系列可转换优先股和该等认股权证优先股在替代转换时转换 当时有效的价格,不考虑指定证书中规定的任何转换限制)不会导致 授权股份失效(定义见指定证书);
(xi)在权益状况计量期间的每 天,不应发生且不应存在触发事件( 在指定证书中定义)或随着时间的推移或发出通知将构成 触发事件的事件(无论持有人是否已提交触发事件赎回通知(定义见指定证书),如适用);
17
(xii)根据证券购买协议发行的所有优先股转换后可发行的 普通股股票,以及在行使SPA优先认股权证时可发行的 普通股股票均经正式授权和上市,且有资格在合资格市场上不受限制地交易 (假设为此目的,所有的优先股,都是这样的优先股,都是这样的。按当时有效的替代转换价格转换,且不考虑 指定证书中规定的转换限制);
(xiii)A系列可换股优先股、SPA优先认股权证或普通认股权证持有人、本公司、主要市场之间不存在任何真诚争议(或本公司普通股当时 主要交易的适用合资格市场)和/或FINRA有关指定证书、任何SPA优先 认股权证的任何条款或规定,任何普通认股权证或任何其他交易文件;及
(xiv)在 股权状况计量期内,不应发生后续配售(定义见证券购买协议 )(除外证券(定义见证券购买协议)除外)。
(k) “股权条件失效”是指自适用强制行使通知日期 前二十(20)个交易日起至适用强制行使日期(包括适用强制行使日期)的期间内的每一天,股权条件尚未 得到满足(或持有人书面放弃)。
(l) "到期日"是指发行日的两(2)周年纪念日(或经本公司和持有人书面同意延长的较后日期 ),或者,如果该日期是交易日以外的一天,或 在主要市场上没有交易("假日"),则指非假日的下一个日期。
18
(m) “Fundamental Transaction” means (A) that the Company shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving corporation) another Subject Entity, or (ii) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company or any of its “significant subsidiaries” (as defined in Rule 1-02 of Regulation S-X) to one or more Subject Entities, or (iii) make, or allow one or more Subject Entities to make, or allow the Company to be subject to or have its Common Shares be subject to or party to one or more Subject Entities making, a purchase, tender or exchange offer that is accepted by the holders of at least either (x) 50% of the outstanding Common Shares, (y) 50% of the outstanding Common Shares calculated as if any Common Shares held by all Subject Entities making or party to, or Affiliated with any Subject Entities making or party to, such purchase, tender or exchange offer were not outstanding; or (z) such number of Common Shares such that all Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such purchase, tender or exchange offer, become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934 Act) of at least 50% of the outstanding Common Shares, or (iv) consummate a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with one or more Subject Entities whereby all such Subject Entities, individually or in the aggregate, acquire, either (x) at least 50% of the outstanding Common Shares, (y) at least 50% of the outstanding Common Shares calculated as if any Common Shares held by all the Subject Entities making or party to, or Affiliated with any Subject Entity making or party to, such stock purchase agreement or other business combination were not outstanding; or (z) such number of Common Shares such that the Subject Entities become collectively the beneficial owners (as defined in Rule 13d-3 under the 1934 Act) of at least 50% of the outstanding Common Shares, or (v) reorganize, recapitalize or reclassify its Common Shares, (B) that the Company shall, directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, allow any Subject Entity individually or the Subject Entities in the aggregate to be or become the “beneficial owner” (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, whether through acquisition, purchase, assignment, conveyance, tender, tender offer, exchange, reduction in outstanding Common Shares, merger, consolidation, business combination, reorganization, recapitalization, spin-off, scheme of arrangement, reorganization, recapitalization or reclassification or otherwise in any manner whatsoever, of either (x) at least 50% of the aggregate ordinary voting power represented by issued and outstanding Common Shares, (y) at least 50% of the aggregate ordinary voting power represented by issued and outstanding Common Shares not held by all such Subject Entities as of the date of this Warrant calculated as if any Common Shares held by all such Subject Entities were not outstanding, or (z) a percentage of the aggregate ordinary voting power represented by issued and outstanding Common Shares or other equity securities of the Company sufficient to allow such Subject Entities to effect a statutory short form merger or other transaction requiring other shareholders of the Company to surrender their Common Shares without approval of the shareholders of the Company or (C) directly or indirectly, including through subsidiaries, Affiliates or otherwise, in one or more related transactions, the issuance of or the entering into any other instrument or transaction structured in a manner to circumvent, or that circumvents, the intent of this definition in which case this definition shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this definition to the extent necessary to correct this definition or any portion of this definition which may be defective or inconsistent with the intended treatment of such instrument or transaction.
(n) "集团"指1934年法案第13(d)条中使用的术语以及 规则13d—5中的定义。
(o)“持有人按税率金额”指以下分数:(i)其分子为在截止日期向持有人发行的A系列可换股优先股 总数;(ii)其分母为在截止日期根据证券购买协议向初始购买人发行的A系列可换股优先股总数。
19
(p) 个人的"母实体"是指直接或间接控制适用个人的实体,且 其普通股或同等股本证券在合格市场上报价或上市,或者,如果存在多个此类个人 或母实体,则指截至基本 交易完成之日具有最大公开市值的个人或母实体。
(q) "个人"是指个人、有限责任公司、合伙企业、合资企业、公司、信托、非法人组织、任何其他实体或政府或其任何部门或机构。
(r) "价格失效"是指,就特定的确定日期而言,在紧接该 确定日期前一个交易日结束的二十(20)个交易日期间, 任何连续三(3)个交易日的普通股VWAP未能超过最低价(如指定证书中的定义)(根据股票分割、股票股息、股票合并、资本重组或认购日期之后发生的其他类似交易进行调整)。所有此类决定 均应在任何此类计量期间内对任何股票拆分、股票股息、股票合并、资本重组或其他类似交易进行适当调整。
(S) 主体市场是指纳斯达克资本市场。
(t) "期权"指认购或购买普通股或可转换证券 (定义见证券购买协议)的任何权利、认股权证或期权。
(u) “SEC”指美国证券交易委员会或其继承者。
(v) "A系列可转换优先股"指(i)公司的A系列可转换优先股, 每股面值0.01美元,根据A系列指定证书发行和可发行的,以及(ii) 该系列A可转换优先股将被变更为的任何股本,或因该系列重新分类而产生的任何股本 A可转换优先股。
(w) "主体实体"指任何个人、个人或团体,或任何此类个人、个人 或团体的任何关联机构或联营公司。
(x) "继承实体"是指由任何基本交易形成、产生或存续的人(或,如果持有人选择,母实体),或与该基本交易进行的人(或,如果持有人选择,母实体)。
20
(y) "交易日"指(如适用)(x)就与普通股有关的所有价格或交易量确定而言,普通股在主要市场交易的任何一天,或者,如果主要市场不是普通股的主要 交易市场,则指在主要证券交易所或当时进行普通股交易的证券市场上交易的任何一天,但"交易日"不包括普通股计划在该交易所 或市场交易少于4.5小时的任何日子,或在该交易所或市场交易的最后一小时内暂停交易的任何日子(或如果该交易所或市场未事先指定该交易所或市场交易的收盘时间, 然后在下午4:00:00结束的一小时内,纽约时间),除非 持有人另行书面指定该日为交易日,或(y)就与普通股有关的所有决定(价格或交易量决定除外),纽约证券交易所(或其任何后继者)开放证券交易的任何 日。
(Z) “成交量故障”指,就特定确定日期而言,普通股在截至该确定日期前一个交易日止的二十(Br)(20)个交易日期间(该期间为“成交量 故障衡量期间”)内,于主要市场连续三(3)个交易日的每日美元总成交量(如彭博所述)少于25,000美元。
(A) “VWAP”指截至任何日期的任何证券在纽约时间上午9:30开始至下午4:00止的期间内,该证券在主要市场(或如主要市场不是该证券的主要交易市场,则指当时交易该证券的主要证券交易所或证券市场)的美元成交量加权平均价。如彭博社通过其“VAP”功能(设置为09:30开始时间和16:00结束时间) ,或者,如果上述规定不适用,则为自纽约时间上午9:30起至纽约时间下午4:00止这段时间内此类证券在场外交易市场上此类证券的美元成交量加权平均价格,如彭博社报道的 ,或者,如果彭博在该时间内未报告此类证券的美元成交量加权平均价格,粉色公开市场(或继承其报告价格职能的类似组织或机构)报告的此类证券的任何做市商的最高收盘价和最低收盘价的平均值。如未能在该日期按上述任何基准计算该证券的VWAP,则该证券在该日期的VWAP应为本公司与持有人共同厘定的公平市价。如果公司和持有人无法就此类证券的公允市场价值达成一致,则应按照第14节的程序解决争议。所有此类决定应针对该期间的任何股息、股份拆分、股份合并、资本重组或其他类似交易进行适当的 调整。
[签名页面如下]
21
兹证明,本公司已安排本认股权证购买A系列可转换优先股,并于上述发行日期正式签立。
LTD. | |||
发信人: | |||
姓名: | |||
标题: |
附件A
行使通知
由登记持有人 执行,以行使本 承诺购买A系列可换股优先股
LYTUS 科技控股PTV。LTD.
签署人在此选择行使认股权证购买A系列可转换优先股,编号:[](“Lytus技术控股公司PTV的授权证“)。有限公司,一家根据英属维尔京群岛法律组建的公司(“公司”),具体如下:此处使用的大写术语和未另行定义的术语应具有本认股权证中规定的各自含义。
1.行权价支付 。根据认股权证的条款,持有人应向本公司支付合计行使价_美元。
2.交付权证优先股 。本公司应根据认股权证的条款,向持有人或其指定代理人或以下指定代理人交付_股A系列可转换优先股。应将以下名称和地址的证书作为证书交付给持有人或为持有人的利益而交付:
签发给: | ||
日期:_ | ||
登记持有人姓名或名称 | ||
发信人: | ||
姓名: | ||
标题: | ||
税号: | ||
电子邮件地址: |